Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1(19)

Página do item simplificado
dc.citation.issue18
dc.citation.volume35
dc.contributor.authorRocha, Mariana Vilela
dc.contributor.authorFrancoso, Katia Sanches
dc.contributor.authorLima, Luciana Chagas
dc.contributor.authorCamargo, Tarsila Mendes
dc.contributor.authorMachado, Ricardo L. D.
dc.contributor.authorCosta, Fabio T. M.
dc.contributor.authorRenia, Laurent
dc.contributor.authorNosten, Francois
dc.contributor.authorRussell, Bruce
dc.contributor.authorRodrigues, Mauricio M. [UNIFESP]
dc.contributor.authorSoares, Irene S.
dc.coverageOxford
dc.date.accessioned2020-07-17T14:02:15Z
dc.date.available2020-07-17T14:02:15Z
dc.date.issued2017
dc.description.abstractPlasmodium vivax is the most widely distributed malaria species and the most prevalent species of malaria in America and Asia. Vaccine development against P. vivax is considered a priority in the global program for the eradication of malaria. Earlier studies have characterized the Apical Membrane Antigen 1 (AMA-1) ectodomain and the C-terminal region (19 kDa) of the Merozoite Surface Protein 1 (MSP-1) of P. vivax as immunodominant antigens. Based on this characterization, we designed a chimeric recombinant protein containing both merozoite immunodominant domains (PvAMA1(66)-MSP1(19)). The recombinant PvAMA166-MSP119 was successfully expressed in Pichia pastoris and used to immunize two different mouse strains (BALB/c and C57BL/6) in the presence of the Poly (I:C) as an adjuvant. Immunization with the chimeric protein induced high antibody titers against both proteins in both strains of mice as detected by ELISA. Antisera also recognized the native proteins expressed on the merozoites of mature P. vivax schizonts. Moreover, this antigen was able to induce IFN-gamma-secreting cells in C57BL/6 mice. These findings indicate that this novel yeast recombinant protein containing PvAMA1(66) and PvMSP1(19) is advantageous, because of improved antibody titers and cellular immune response. Therefore, this formulation should be further developed for pre-clinical trials in non-human primates as a potential candidate for a P. vivax vaccine. (C) 2017 Elsevier Ltd. All rights reserved.en
dc.description.affiliationUniv Sao Paulo, Fac Ciencias Farmaceut, Dept Analises Clin & Toxicol, Sao Paulo, SP, Brazil
dc.description.affiliationInst Evandro Chagas, Div Parasitol, Belem, Para, Brazil
dc.description.affiliationUniv Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, La Doencas Tropicais, Campinas, SP, Brazil
dc.description.affiliationAgcy Sci Technol & Res, Singapore Immunol Network, Biopolis, Singapore, Singapore
dc.description.affiliationMahidol Univ, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Fac Trop Med, Mae Sot, Thailand
dc.description.affiliationUniv Oxford, Nuffield Dept Med Res Bldg, Ctr Trop Med & Global Hlth, Old Rd Campus, Oxford, England
dc.description.affiliationUniv Otago, Dept Microbiol & Immunol, Dunedin, New Zealand
dc.description.affiliationUniv Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, CTCMOL, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, CTCMOL, Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
dc.description.sponsorshipInstituto Nacional de Ciencia e Tecnologia de Vacinas (INCTV)
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
dc.description.sponsorshipFAPESP
dc.description.sponsorshipCNPq
dc.description.sponsorshipCAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)
dc.description.sponsorshipIDCNPq: 475500/2012-1
dc.description.sponsorshipIDFAPESP: 012/13032-5
dc.description.sponsorshipIDFAPESP: 2011/23278-9
dc.description.sponsorshipIDFAPESP: 2013/01487-0
dc.format.extent2463-2472
dc.identifierhttp://dx.doi.org/10.1016/j.vaccine.2017.03.023
dc.identifier.citationVaccine. Oxford, v. 35, n. 18, p. 2463-2472, 2017.
dc.identifier.doi10.1016/j.vaccine.2017.03.023
dc.identifier.issn0264-410X
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/54709
dc.identifier.wosWOS:000400715600028
dc.language.isoeng
dc.publisherElsevier Sci Ltd
dc.relation.ispartofVaccine
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectMalariaen
dc.subjectPlasmodium vivaxen
dc.subjectRecombinant vaccineen
dc.titleGeneration, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1(19)en
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos